Molecular Neurodegeneration, 1750-1326

Journal

More filtering options
  1. 2017
  2. Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

    Portelius, E., Niklas Mattsson, Pannee, J., Zetterberg, H., Gisslén, M., Vanderstichele, H., Gkanatsiou, E., Crespi, G. A. N., Parker, M. W., Miles, L. A., Gobom, J. & Blennow, K., 2017 Feb 20, In : Molecular Neurodegeneration. 12, 1, p. 1-11 18.

    Research output: Contribution to journalArticle

  3. Aβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A

    Willén, K., Edgar, J. R., Hasegawa, T., Tanaka, N., Futter, C. E. & Gunnar K Gouras, 2017, In : Molecular Neurodegeneration. 12, 61.

    Research output: Contribution to journalArticle

  4. 2016
  5. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein

    Landeck, N., Hall, H., Ardah, M. T., Majbour, N. K., El-Agnaf, O. M. A., Halliday, G. & Deniz Kirik, 2016 Aug 22, In : Molecular Neurodegeneration. 11, 1, 125.

    Research output: Contribution to journalArticle

  6. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease

    Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Johan Svensson, Per Johansson, Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., Mills, K. & Zetterberg, H., 2016, In : Molecular Neurodegeneration. 11, p. 1-7 3.

    Research output: Contribution to journalArticle

  7. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.

    Majbour, N. K., Nishant N. Vaikath, van Dijk, K. D., Ardah, M. T., Varghese, S., Vesterager, L. B., Montezinho, L. P., Poole, S., Safieh-Garabedian, B., Tokuda, T., Teunissen, C. E., Berendse, H. W., van de Berg, W. D. J. & El-Agnaf, O. M. A., 2016, In : Molecular Neurodegeneration. 11, 1, 7.

    Research output: Contribution to journalArticle

  8. 2015
  9. Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid.

    Barbariga, M., Curnis, F., Andolfo, A., Zanardi, A., Lazzaro, M., Conti, A., Magnani, G., Volontè, M. A., Ferrari, L., Comi, G., Corti, A. & Alessio, M., 2015, In : Molecular Neurodegeneration. 10, 1, 59.

    Research output: Contribution to journalArticle

  10. 2014
  11. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease

    Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frolich, L., Hausner, L., Lennart Minthon, Oskar Hansson, Wallin, A., Zetterberg, H., Blennow, K. & Ohrfelt, A., 2014, In : Molecular Neurodegeneration. 9, 53.

    Research output: Contribution to journalArticle

  12. 2013
  13. Fluid biomarkers in Alzheimer's disease - current concepts

    Rosen, C., Oskar Hansson, Blennow, K. & Zetterberg, H., 2013, In : Molecular Neurodegeneration. 8, 20.

    Research output: Contribution to journalReview article

  14. 2010
  15. BACE1 gene variants do not influence BACE1 activity, levels of APP or A beta isoforms in CSF in Alzheimer's disease

    Sjolander, A., Zetterberg, H., Andreasson, U., Lennart Minthon & Blennow, K., 2010, In : Molecular Neurodegeneration. 5

    Research output: Contribution to journalArticle

  16. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease

    Portelius, E., Andreasson, U., Ringman, J. M., Buerger, K., Daborg, J., Buchhave, P., Oskar Hansson, Harmsen, A., Gustavsson, M. K., Hanse, E., Galasko, D., Hampel, H., Blennow, K. & Zetterberg, H., 2010, In : Molecular Neurodegeneration. 5

    Research output: Contribution to journalArticle

  17. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease

    Zetterberg, M., Sjolander, A., von Otter, M., Palmer, M. S., Landgren, S., Lennart Minthon, Wallin, A., Andreasen, N., Blennow, K. & Zetterberg, H., 2010, In : Molecular Neurodegeneration. 5

    Research output: Contribution to journalArticle